Tribunal partially allows appeal, remits key tax issues for reassessment.

The Tribunal partly allowed the appeal of the assessee, remitting various issues back to the Assessing Officer for fresh consideration. Key matters included the treatment of depreciation on intangible assets acquired from Orchid India, non-compete fee eligibility, expenses for capacity expansion, pricing adjustments for shipments, interest benchmarking for ICCD, profit-sharing ratio adjustments based on a Settlement Commission order, and the application of Section 92A(2)(i) for sales made to third parties. The Tribunal emphasized adherence to the law in reconsidering these issues.

---

---

Issues Involved:
1. Depreciation on intangible assets.
2. Disallowance of non-compete fee.
3. Disallowance of expenses paid towards capacity expansion.
4. Downward adjustment for difference between cost of shipment with standard price.
5. Methodology for benchmarking interest payment for Indian Compulsorily Convertible Debentures (ICCD).
6. Adoption of Order of Settlement Commission for profit sharing ratio.
7. Application of Section 92A(2)(i) for sales made to third parties.

Detailed Analysis:

1. Depreciation on Intangible Assets:
The assessee contended that the depreciation on intangible assets, such as developed products, in-process research and development, customer relationships, and contract manufacturing, acquired from Orchid India should be allowed under Section 32 of the Income Tax Act. The Assessing Officer (AO) disallowed this claim, arguing that the valuation was not scientific and the intangible assets could not be independently sold. The Tribunal remitted the issue back to the AO for fresh consideration, emphasizing that the conditions set out by the AO applied only to internally generated intangible assets, not those acquired by payment.

2. Disallowance of Non-Compete Fee:
The assessee claimed the non-compete fee paid to Mr. K. Raghavendra Rao as a revenue outgo. The AO disallowed this, treating it as not eligible for depreciation. The Tribunal noted that the lower authorities had not carefully verified the relevant agreements and remitted the issue back to the AO for fresh consideration, citing the need to determine whether the non-compete fee was a supporting clause to the transfer of the injectable drugs division.

3. Disallowance of Expenses Paid Towards Capacity Expansion:
The assessee paid a sum to Orchid India to ensure a continuous supply of essential API and claimed it as a revenue expenditure. The AO treated this as a capital expenditure. The Tribunal allowed the assessee's claim, stating that the payment was in the revenue field to ensure the supply of raw materials and did not enhance the assessee's asset structure.

4. Downward Adjustment for Difference Between Cost of Shipment with Standard Price:
The AO made an upward adjustment for deficiencies in the pricing of supplies to Associated Enterprises (AEs) abroad. The assessee argued that the AO only considered negative differences, ignoring positive ones. The Tribunal remitted the issue back to the AO/TPO for fresh consideration, emphasizing the need to consider both positive and negative price differences.

5. Methodology for Benchmarking Interest Payment for ICCD:
The AO made a downward adjustment on interest paid by the assessee to its AE for ICCD, using interest rates from two companies for comparison. The assessee argued that the comparables used were not appropriate. The Tribunal remitted the issue back to the AO/TPO for fresh consideration, noting discrepancies in the interest rates considered.

6. Adoption of Order of Settlement Commission for Profit Sharing Ratio:
The AO followed a Settlement Commission order to adjust the profit-sharing ratio between the assessee and its AEs. The assessee argued that the Settlement Commission's order should not be applied without independent assessment. The Tribunal remitted the issue back to the AO/TPO for fresh consideration, emphasizing the need to apply Rule 10B(d) of the Income Tax Rules correctly.

7. Application of Section 92A(2)(i) for Sales Made to Third Parties:
The AO treated Apotex Corp and Apotex Inc as AEs of the assessee, applying Section 92A(2)(i). The assessee argued that these companies were not AEs as there was no dominant influence. The Tribunal upheld the AO's decision, stating that Apotex Corp and Apotex Inc had a dominant influence over the assessee due to their significant share in the assessee's sales. However, the Tribunal remitted the issue of profit split ratio back to the AO/TPO for fresh consideration.

Conclusion:
The Tribunal allowed the appeal of the assessee partly for statistical purposes, remitting several issues back to the AO for fresh consideration in accordance with the law. The key issues involved were the treatment of depreciation on intangible assets, non-compete fees, capacity expansion expenses, pricing adjustments, interest benchmarking, and the application of profit-sharing ratios and associated enterprise definitions.

---